Search
Onvansertib
go.drugbank.com/drugs/DB15110InvestigationalOnvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
Synonyms: 1-(2-Hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamideCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingUtomilumab
go.drugbank.com/drugs/DB15113InvestigationalUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigationalZolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
PF-05241328
go.drugbank.com/drugs/DB15124InvestigationalPF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound
Remtolumab
go.drugbank.com/drugs/DB15128InvestigationalRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12
Interferon alfa-2c
go.drugbank.com/drugs/DB15131InvestigationalInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: Intron-AAZD-9496
go.drugbank.com/drugs/DB15138InvestigationalAZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).
Categories: Heterocyclic Compounds, 2-RingAltropane I-123
go.drugbank.com/drugs/DB15144InvestigationalAltropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the
Synonyms: Altropane I-123Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFutibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and … [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 1-((3S)-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3, 4-d) pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-onePepinemab
go.drugbank.com/drugs/DB15155InvestigationalPepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).